Companies: 10,795·Total market cap: $144.5T
Summit Therapeutics Inc.

Summit Therapeutics Inc.

SMMTNASDAQHealthcare● Active
$14.77
$-0.07(-0.47%)
Market Cap$11.5B
P/E Ratio—
52W High$30.98
52W Low$13.83
Overview
Stock ranking:Biotechnology·Healthcare·View All Market Cap Rankings →

Summit Therapeutics Inc. (SMMT) Stock Overview

Key statistics and deep links to earnings, valuation, revenue, dividends, and more.

FMP · SMMT · as of Jun 8, 2026

Key Statistics

EPS (TTM)$-1.40smmt eps ttm · smmt earnings per shareEarnings history
PE Ratio (TTM)—smmt pe ratio ttm · smmt price to earningsPE Ratio deep dive
Revenue (TTM)0.00smmt revenue ttm · smmt annual revenueFull revenue history
Dividend YieldNo Dividenddoes smmt pay dividends · smmt dividend yieldDividend history
Shares Outstanding747.7Msmmt shares outstanding · smmt floatShares outstanding history
Next EarningsAug 10, 2026Est.smmt earnings date · smmt next earningsEarnings history

Explore Summit Therapeutics Inc. Data

smmt stock data · financials
Market Cap$11.5Bsmmt market cap · smmt valuation
Analyst Forecast$19 · Buy
DividendsNo Dividenddoes summit therapeutics inc. pay dividends · smmt dividend yield
Revenue—summit therapeutics inc. annual revenue · smmt revenue
EarningsEPS $-1.44-476.00%smmt earnings · smmt eps
PE Ratio—smmt pe ratio · smmt price to earnings

Financial Snapshot

Full Financials
FY 2025Revenue$0.00
202320242025
summit therapeutics inc. revenue · smmt revenue 2025
FY 2025Net Income-$1.08B▼ 510.72% YoY
202320242025
summit therapeutics inc. net income · smmt profit 2025
FY 2025EPS$-1.44▼ 476.00% YoY
202320242025
smmt eps · summit therapeutics inc. earnings per share 2025
TTM:Revenue: $0.00Net Income: -$1.05BEPS: $-1.40View income statement →

Analyst Ratings & Price Target

Full Forecast
SellBuy
Buy21 analystsis smmt a buy · smmt analyst rating
Strong Buy
0
Buy
14
Hold
7
Sell
0
Strong Sell
0
12-Month Price Target
$16.00Low
$14.77Current
$19.00Avg Target28.64% upside
$23.00High
smmt price target · smmt 12 month forecast

Total: 21 · Buy rate: 66.7%

The SMMT analyst consensus is Buy, based on ratings from 21 Wall Street analysts over the past 3 months. The average 12-month price target is $19.00, representing +28.64% upside from the current price of $14.77.

Stock Performance

Full History
1D-0.47%
1W+0.14%
1M-18.31%
3M-2.25%
YTD-15.55%
1Y-31.49%
5Y+92.82%

About Summit Therapeutics Inc.

CEORobert W. Duggan
IPO DateMar 5, 2015
Employees159
CountryUS
Websitesummittxinc.com

Summit Therapeutics Inc. a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical progr…

BiotechnologyHealthcareNASDAQUS

what is summit therapeutics inc. · smmt stock overview · summit therapeutics inc. company profile · who is summit therapeutics inc. ceo · smmt NASDAQ · summit therapeutics inc. headquarters · summit therapeutics inc. business segments

About Stock Overview & Key Data

Summit Therapeutics Inc. (SMMT) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Mar 5, 2015. As of the latest trading session, SMMT stock price is $14.77, with a market capitalization of $11.5B. The stock has returned -31.49% over the past 12 months and -15.55% year-to-date.

According to 21 Wall Street analysts, the consensus rating for Summit Therapeutics Inc. stock is Buy, with an average 12-month price target of $19.00. In fiscal year 2025, Summit Therapeutics Inc. reported revenue of — and net income of -$1.1B. For detailed data — including Summit Therapeutics Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.

Frequently Asked Questions

As of the latest trading session, Summit Therapeutics Inc. (SMMT) stock price is $14.77. The stock is traded on NASDAQ under the ticker symbol SMMT. The 52-week range is $13.83 – $30.98.

SMMT stock priceSMMT quote todaylive ticker
Data provided by Financial Modeling PrepLast updated: Jun 8, 2026Not investment advice